IL33 and Alzheimer disease: In patients with CRSwNP, IL-5, IgE, CCL17, CCL26, ILC2s, and circulating eosinophils and basophils were measured, while in patients with AD, IgE, CCL17, and hsCRP were monitored to assess any PF-06817024-mediated effect on IL-33 downstream activities.